Probiotics: Strains, Products & Condition-Specific Evidence

A probiotic is best treated as a named biological intervention: genus + species + strain + dose + population + outcome. A 100-billion-CFU bottle with 15 organisms can have a weaker evidence bridge than a simpler product that identifies one studied strain.

What gastroenterology guidelines actually say

Professional guidance is much narrower than probiotic advertising.

During antibiotics and C. difficile prevention

The American Gastroenterological Association suggests several specific strains or formulations for adults and children receiving antibiotics when the goal is prevention of Clostridioides difficile infection. Those options include Saccharomyces boulardii and several defined bacterial combinations.

This is not a blanket recommendation for every probiotic sold beside an antibiotic. If the retail product does not match the studied organism or formulation closely enough, that mismatch needs to remain visible.

For active C. difficile infection, AGA recommends probiotics only in a clinical-trial context. Significant post-antibiotic diarrhea needs proper evaluation, not supplement-only treatment.

IBS

The American College of Gastroenterology does not recommend routine probiotic use for global IBS symptoms because results are inconsistent and evidence quality is low.

That does not mean every strain has zero useful evidence. It means a shopper should not jump from a positive study on one strain and endpoint to “probiotics treat IBS.”

For example, Align 24/7 Digestive Support identifies Bifidobacterium 35624 and has a positive IBS trial at a studied dose, while a separate trial in people without IBS did not significantly improve mean abdominal discomfort or bloating severity. The population matters.

Recurrent pouchitis

For people with recurrent antibiotic-responsive pouchitis after ileal pouch-anal anastomosis, AGA suggests probiotics for prevention of recurrence, conditionally and with low-certainty evidence. The guideline specifically notes that trials used the De Simone Formulation.

Visbiome GI Care is therefore an unusually clean formulation-level comparator because it identifies the De Simone Formulation and its eight strains. That evidence is narrow and medically supervised; it does not make Visbiome a default probiotic for everyday bloating.

Medical guidance and integrative/naturopathic practice: where they overlap

Academic integrative medicine and accredited naturopathic training environments commonly discuss probiotics as part of selected digestive-health plans. The better examples do not treat every probiotic as interchangeable.

The University of Arizona’s Andrew Weil Center for Integrative Medicine advises checking the genus, species and strain, viability and condition-specific dose. Bastyr describes digestive care that may include specific probiotics alongside dietary interventions, herbs, supplements and targeted medication. Naturopathic clinician education from AANMC likewise describes choosing specific probiotics studied for particular gastrointestinal conditions.

That overlap with conventional evidence is useful: specificity beats ideology.

Where practice styles diverge is breadth of use. Some integrative or naturopathic clinicians use probiotics more frequently for symptom patterns or microbiome-oriented protocols than gastroenterology guidelines support. That practice context is relevant, but it is not proof of efficacy.

Product examples and evidence matching

Florastor Dual Action — CNCM I-745 strain identity disclosed

Florastor Dual Action discloses S. boulardii CNCM I-745. That makes published CNCM I-745 evidence much easier to map to the bottle than products that list only “S. boulardii.”

AGA’s antibiotic-period guidance includes S. boulardii as an option, but it does not endorse Florastor as a retail brand. The distinction matters.

Bio-K+ Advanced Bowel Support — named strains plus an important negative trial

Bio-K+ Advanced Bowel Support identifies CL1285, LBC80R and CLR2 and guarantees 50 billion CFU through expiration. AGA guidance names the CL1285 + LBC80R combination among its antibiotic-period options.

But a later large hospital cluster-randomized trial of the three-strain Bio-K+ program did not significantly reduce hospital-acquired C. difficile infection after adjustment. The negative result belongs beside the positive guideline context because the two sources answer different questions.

Visbiome GI Care — De Simone Formulation identified

Visbiome GI Care provides 112.5 billion CFU per capsule of the eight-strain De Simone Formulation and uses refrigerated cold-chain handling.

Its most compelling evidence story is recurrent pouchitis prevention—not generic “gut health.” Older studies may call the tested formulation VSL#3; evidence reviews warn that the formulation historically studied under that name is now sold in the United States as the De Simone Formulation/Visbiome rather than the current VSL#3 product.

Align — a good lesson in population-specific evidence

Align 24/7 Digestive Support identifies Bifidobacterium 35624. A positive IBS trial and a neutral non-IBS study make it useful precisely because the evidence is mixed in an interpretable way.

Culturelle — do not generalize LGG beyond the endpoint studied

Culturelle Digestive Daily contains Lactobacillus rhamnosus GG (LGG), one of the better-known probiotic strains. An LGG study that fails for one hospital infection-related endpoint does not erase all LGG research—and a positive LGG result elsewhere does not prove every claim on a retail bottle.

Klaire Labs / SFI Health: practitioner products under an evidence microscope

The Ther-Biotic line has deep practitioner recognition, but “practitioner grade” is not an evidence category.

Ther-Biotic Complete

Ther-Biotic Complete supplies 25 billion CFU from 12 species and is refrigerated. The current US page gives a detailed species breakdown but no strain designations. That limits strain-specific trial mapping.

Ther-Biotic Synbiotic

Ther-Biotic Synbiotic is stronger on transparency: 50 billion CFU with several named strains including LGG, DDS-1, UALp-05, UABla-12 and UALre-16, plus 200 mg PHGG.

The PHGG amount needs perspective: a placebo-controlled IBS trial used 6 g/day—30 times the amount in one capsule—and improved bloating but not overall IBS severity or quality of life.

Ther-Biotic Saccharomyces boulardii

Ther-Biotic Saccharomyces boulardii provides 3 billion CFU, but the current product page does not identify the strain. It should not inherit CNCM I-745 evidence merely because both products say S. boulardii.

Ther-Biotic ABx Support

Ther-Biotic ABx Support combines S. boulardii with L. rhamnosus, B. bifidum and B. breve for 10 billion CFU. Its use case overlaps with antibiotic-period probiotic guidance, but the blend and strain disclosure do not exactly match the formulations named by AGA.

What to look for on a probiotic label

Prefer products that let you answer all of these questions:

1. What exact strain is present? “L. rhamnosus” is less useful than “L. rhamnosus GG.”
2. How many viable organisms are guaranteed at the end of shelf life? A manufacture-date count can be less informative.
3. What dose was studied for the outcome you care about? More CFU is not automatically better.
4. Does the retail formula match the trial? A similar species list is not enough.
5. What population was studied? IBS, healthy adults, hospitalized patients and children are not interchangeable.
6. Was the primary endpoint actually improved? Secondary or microbiome-marker changes should not be promoted as symptom benefit.
7. Is there meaningful negative evidence? A useful comparison should show it.

Safety: who should be more cautious

Most healthy people tolerate probiotics reasonably well, but the risk is not zero. NIH notes that serious infections occur mainly in people with severe illness or compromised immune systems.

Extra caution is appropriate with:

• critical illness or intensive-care treatment;
• major immune compromise;
• central venous catheters, especially with live yeast probiotics;
• very premature infants;
• severe acute gastrointestinal illness;
• a history suggesting a supplement could delay urgent diagnosis.

The FDA has specifically warned about invasive, potentially fatal infections from probiotic organisms in preterm infants. Neonatal probiotic use belongs to specialist care, not consumer supplementation.

When food may be the more sensible first step

If you are generally healthy and simply want a more microbe-supportive diet, fermented foods and a diverse fiber-rich diet may be a better starting point than a permanent capsule subscription.

A supplement becomes more compelling when there is a specific goal with a strain/formulation that has reasonably matched evidence.

For the substrate side of the microbiome, continue to Prebiotics: Fiber Types, Doses & Products. For the combined overview, see Probiotics, Prebiotics & Digestive Enzymes.